Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control
- PMID: 24446486
- PMCID: PMC3989637
- DOI: 10.1002/embj.201385902
Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control
Abstract
Mitochondrial dysfunction has long been associated with Parkinson's disease (PD). Parkin and PINK1, two genes associated with familial PD, have been implicated in the degradation of depolarized mitochondria via autophagy (mitophagy). Here, we describe the involvement of parkin and PINK1 in a vesicular pathway regulating mitochondrial quality control. This pathway is distinct from canonical mitophagy and is triggered by the generation of oxidative stress from within mitochondria. Wild-type but not PD-linked mutant parkin supports the biogenesis of a population of mitochondria-derived vesicles (MDVs), which bud off mitochondria and contain a specific repertoire of cargo proteins. These MDVs require PINK1 expression and ultimately target to lysosomes for degradation. We hypothesize that loss of this parkin- and PINK1-dependent trafficking mechanism impairs the ability of mitochondria to selectively degrade oxidized and damaged proteins leading, over time, to the mitochondrial dysfunction noted in PD.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f1.gif)
Schematic depicting the location of relevant protein markers relative to the mitochondrion, as well as the site of action of pharmacological agents used.
HeLa cells expressing GFP-parkin (green), OCT-DsRed2 (red) and CFP-Drp1K38E were left untreated (untreated) or treated for 2 h with 10 μM CCCP (CCCP), then fixed and stained for TOM20 (blue). Scale bars, 30 μm.
Cells prepared as in (B) were treated with 50 μM antimycin A for 2 h. Arrows indicate OCT-DsRed2-positive/TOM20-negative MDVs that colocalize with GFP-parkin, while circles indicate MDVs that are parkin-negative. Arrowheads indicate “nascent” vesicles, adjacent to mitochondria, exhibiting cargo selectivity and parkin recruitment. Open arrowheads indicate parkin-negative MDVs containing the reciprocal cargo (TOM20-positive/OCT-DsRed2-negative). Cell boundaries are delineated in the GFP-parkin single-channel image. Scale bars, 30 μm.
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f2.gif)
Quantification of the number of OCT-DsRed2-positive/TOM20-negative vesicles in cells expressing GFP, GFP-parkinWT, GFP-parkinR42P, GFP-parkinK211N, or GFP-parkinC431F, treated with or without antimycin A (anti A) as in (C); both the total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Bars represent the mean ± s.e.m. P-values are given first for GFP-/GFP-parkin-positive vesicles, then for total vesicle number (n = 49–68 cells in 2–3 experiments); ns, not significant; **P < 0.01; ***P < 0.001).
Structure of parkin, with PD-linked residues from (D) highlighted in dark gray (PDB ID: 4K95). Ubl, ubiquitin-like domain (red); RING0, RING0 domain (green); RING1, RING1 domain (cyan); IBR, in-between RING (magenta); REP, repressor element of parkin (yellow); RING2, RING2 domain (salmon).
HeLa cells expressing various GFP-parkin mutant contructs (green), pOCT-DsRed2 (red) and CFP-Drp1K38E were treated with 50 μM antimycin A for 2 h, then fixed and immunostained against TOM20. Arrows indicate matrix-positive/TOM20-negative structures colocalizing with GFP-parkin. Scale bars, 30 μm.
Immunoblot of whole-cell lysates of HeLa cells expressing various GFP-parkin constructs, treated with 50 μM antimycin A (anti A, +) or DMSO (−) for 2 h.
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f3.gif)
Representative immunoblot of whole-cell lysates from U2OS:GFP and U2OS:GFP-parkin cells transfected with non-targeting siRNA or siRNA targeting Drp1 (siDrp1).
U2OS:GFP-parkin cells transfected with siRNA targeting Drp1 were treated with DMSO (upper panels) or 25 μM antimycin A (anti A, lower panels) for 90 min, then fixed and immunostained against PDH (red) and TOM20 (blue). PDH E2/E3 bp-positive/TOM20-negative MDVs colocalizing with GFP-parkin (arrows) or not (circles) are indicated. Scale bars, 20 μm (first panels on left) and 2 μm.
Quantification of PDH-positive/TOM20-negative vesicles in U2OS:GFP and U2OS:GFP-parkin cells transfected with the indicated siRNA, treated with DMSO or antimycin A (anti A) as in (B); both the total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Bars represent the mean ± s.e.m. P-values are given first for GFP-/GFP-parkin-positive vesicles, then for total vesicle number (n = 48–85 cells in 2–3 experiments); ns, not significant; ***P < 0.001).
5 μm-long profile of the parkin-positive vesicle and adjacent mitochondrial tubule depicted in the antimycin A-treated cell from (B) (left). Increasing position values on the x-axis of the fluorescence intensity plot (right) correspond to moving from the top to the bottom of the profile. *MDV indicated by an arrow in (B).
Quantification of the distance between the centres of GFP-parkin-negative (black bar) or -positive (gray bar) vesicles and the edge of the nearest mitochondrial tubule for the vesicles quantified in antimycin A-treated U2OS:GFP-parkin cells transfected with siDrp1 in (C). Error bars represent the mean ± s.e.m.; *P < 0.05 (obtained by Student's t-test).
U2OS:GFP-parkin cells transfected with siRNA targeting Drp1 (siDrp1) were treated with 25 μM antimycin A for 90 min prior to fixation. Samples were immunostained against TOM20 (blue) and the indicated mitochondrial marker (red). TOM20-negative MDVs containing the specified cargo and colocalizing with GFP-parkin (arrows) or not (circles) are indicated. Arrowheads show lack of colocalization between GFP-parkin and the indicated mitochondrial marker. Scale bars, 20 μm (first two columns of panels) and 2 μm (remaining columns of panels).
Quantification of TOM20-negative structures that stained positively for the indicated cargo in U2OS:GFP (GFP) and U2OS:GFP-parkin (GFP-parkin) cells, transfected with siRNA targeting Drp1, treated with antimycin A (anti A); both the total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Error bars represent the mean ± s.e.m. P-values are given first for GFP-/GFP-parkin-positive vesicles, then for total vesicle number (n = 24–59 cells in two experiments; ns, not significant; ***P < 0.001).
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f4.gif)
HeLa cells, transfected with siRNA targeting Drp1 and GFP-parkin (green), were treated with 25 μM antimycin A for 90 min following a 30-min pretreatment with 50 nM bafilomycin A1, then fixed and immunostained against PDH E2/E3 bp (red) and TOM20 (blue). PDH E2/E3 bp-positive/TOM20-negative MDVs colocalizing with GFP-parkin (arrows) or not (circles) are indicated. Scale bar, 30 μm.
Quantification of PDH E2/E3bp-positive/TOM20-negative vesicles in HeLa cells treated with antimycin A in the presence of the lysosomal inhibitors bafilomycin A1 or pepstatin A and E-64d; both total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Bars represent the mean ± s.e.m. P-values are given for total vesicle number (n = 19 to 120 cells in 2–3 experiments; **P < 0.01; ***P < 0.001).
HeLa cells, transfected with GFP-parkin (green) and siRNA targeting Drp1 and Atg5, were treated with 25 μM antimycin A for 90 min, then fixed, immunostained for PDH E2/E3 bp (red) and TOM20 (blue), and counterstained for Hoescht (gray). PDH E2/E3 bp-positive/TOM20-negative MDVs colocalizing with GFP-parkin (arrows) or not (circles) are indicated. Scale bars, 20 μm.
Quantification of PDH E2/E3 bp-positive/TOM20-negative vesicles from HeLa cells transfected with the indicated siRNA; both the total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Error bars represent the mean ± s.e.m. P-values are given for the total vesicle number (n = 42–64 cells in 2–3 experiments); ns, not significant.
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f5.gif)
Representative immunoblot of whole-cell lysates from HeLa cells transfected with non-targeting siRNA or siRNA targeting PINK1 (siPINK1), treated with 10 μM CCCP for 6 h in order to stabilize the PINK1 full-length band.
HeLa cells transfected with GFP-parkin (green) and siRNA targeting PINK1 (siPINK1) or non-targeting control (ctrl siRNA), were treated with 25 μM antimycin A for 90 min, then fixed and immunostained for PDH E2/E3 bp (red) and TOM20 (blue). PDH E2/E3 bp-positive/TOM20-negative MDVs colocalizing with GFP-parkin (arrows) or not (circles) are indicated. Arrowheads indicate parkin-positive MDVs adjacent to mitochondria, possibly budding. Scale bar, 20 μm.
Quantification of PDH E2/E3 bp-positive/TOM20-negative structures from (B); both the total number (white bars) and the number colocalizing with GFP-parkin (gray bars) are indicated. Error bars represent the mean ± s.e.m. P-values are given first for GFP-/GFP-parkin-positive vesicles, then for total vesicle number (n = 42–60 cells in three experiments); ns, not significant; ***P < 0.001).
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f6.gif)
Quantification of TMRM fluorescence by flow cytometry in U2OS:GFP-parkin cells treated with 25 μM antimycin A (anti A), 25 μM antimycin A and 10 μM oligomycin (anti A + oligo), and 20 μM CCCP (CCCP) for the indicated time, represented as a fraction of fluorescence intensity compared to DMSO-treated cells. Error bars represent the mean ± s.e.m. (n = 3 experiments).
U2OS:GFP-parkin cells were treated with DMSO (DMSO), 25 μM antimycin A (anti A), 25 μM antimycin A and 10 μM oligomycin (anti A + oligo), or 20 μM CCCP (CCCP) for two hours, then fixed and immunostained for TOM20 (red). Scale bars, 50 μm.
Quantification of the total number of PDH E2/E3 bp-positive/TOM20-negative structures in U2OS:GFP-parkin cells observed at various times for the indicated treatment. Error bars represent the mean ± s.e.m. (n = 46–166 cells in 2–3 experiments).
U2OS:GFP-parkin cells were treated with DMSO (DMSO), 25 μM antimycin A (anti A), 25 μM antimycin A and 10 μM oligomycin (anti A + oligo), or 20 μM CCCP (CCCP) for two hours, then fixed and immunostained for PDH E2/E3 bp (red) and TOM20 (blue). A merged image of both mitochondrial markers (mito) is shown at the far right. Arrows indicate PDH E2/E3 bp-positive/TOM20-negative structures colocalizing with GFP-parkin (green). Scale bars, 20 μm.
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3989637/bin/embj0033-0282-f7.gif)
Representative immunoblot of whole-cell lysates from U2OS:GFP and GFP-parkin cells treated with DMSO, 25 μM antimycin A (anti A), 25 μM antimycin A with 10 μM oligomycin (anti A + oligo), or 20 μM CCCP for the indicated time period.
Quantification of PDH E1a signal intensity relative to that of actin in immunoblots from (A). Error bars represent the mean ± s.e.m. (n = 3 experiments).
Quantification of mitochondrial clearance in U2OS:GFP-parkin cells treated as in (A), fixed and immunostained for TOM20. Data are shown as percentage of cells containing mitochondria, by TOM20 staining, visualized by fluorescence microscopy. Error bars represent the mean ± s.e.m. (n = 3 experiments, with at least 85 cells quantified per condition, per experiment).
U2OS:GFP-parkin cells were treated as in (A) for the indicated time period, then fixed and immunostained for TOM20 (red). Cell boundaries are delineated in single-channel images. Scale bars, 20 μm.
Comment in
-
Have you seen? For parkin, it's not all or nothing.EMBO J. 2014 Feb 18;33(4):277-9. doi: 10.1002/embj.201387723. Epub 2014 Feb 5. EMBO J. 2014. PMID: 24502976 Free PMC article.
-
Protein degradation: An alternative route for mitochondrial quality control.Nat Rev Mol Cell Biol. 2014 Mar;15(3):150-1. doi: 10.1038/nrm3755. Epub 2014 Feb 12. Nat Rev Mol Cell Biol. 2014. PMID: 24518366 No abstract available.
Similar articles
-
N-degron-mediated degradation and regulation of mitochondrial PINK1 kinase.Curr Genet. 2020 Aug;66(4):693-701. doi: 10.1007/s00294-020-01062-2. Epub 2020 Mar 10. Curr Genet. 2020. PMID: 32157382 Review.
-
Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond.Free Radic Biol Med. 2016 Nov;100:210-222. doi: 10.1016/j.freeradbiomed.2016.04.015. Epub 2016 Apr 16. Free Radic Biol Med. 2016. PMID: 27094585 Review.
-
Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin.J Cell Biol. 2010 Dec 27;191(7):1367-80. doi: 10.1083/jcb.201007013. Epub 2010 Dec 20. J Cell Biol. 2010. PMID: 21173115 Free PMC article.
-
The PINK1/Parkin-mediated mitophagy is compromised by PD-associated mutations.Autophagy. 2010 Oct;6(7):871-8. doi: 10.4161/auto.6.7.13286. Epub 2010 Oct 3. Autophagy. 2010. PMID: 20798600
-
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy.J Cell Biol. 2010 Apr 19;189(2):211-21. doi: 10.1083/jcb.200910140. J Cell Biol. 2010. PMID: 20404107 Free PMC article.
Cited by
-
The structure and function of FUN14 domain-containing protein 1 and its contribution to cardioprotection by mediating mitophagy.Front Pharmacol. 2024 May 17;15:1389953. doi: 10.3389/fphar.2024.1389953. eCollection 2024. Front Pharmacol. 2024. PMID: 38828457 Free PMC article. Review.
-
Evidence of mitochondria origin of SARS-CoV-2 double-membrane vesicles: a review.F1000Res. 2022 Nov 10;10:1009. doi: 10.12688/f1000research.73170.2. eCollection 2021. F1000Res. 2022. PMID: 38827572 Free PMC article. Review.
-
Mitochondrial quality control in human health and disease.Mil Med Res. 2024 May 29;11(1):32. doi: 10.1186/s40779-024-00536-5. Mil Med Res. 2024. PMID: 38812059 Free PMC article. Review.
-
Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction-the trigger for PANoptosis in neurons.Front Aging Neurosci. 2024 May 14;16:1400544. doi: 10.3389/fnagi.2024.1400544. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38808033 Free PMC article. Review.
-
PRKN-linked familial Parkinson's disease: cellular and molecular mechanisms of disease-linked variants.Cell Mol Life Sci. 2024 May 20;81(1):223. doi: 10.1007/s00018-024-05262-8. Cell Mol Life Sci. 2024. PMID: 38767677 Free PMC article. Review.
References
-
- Augustin S, Nolden M, Muller S, Hardt O, Arnold I, Langer T. Characterization of peptides released from mitochondria: evidence for constant proteolysis and peptide efflux. J Biol Chem. 2005;280:2691–2699. - PubMed
-
- d'Azzo A, Bongiovanni A, Nastasi T. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic. 2005;6:429–441. - PubMed
-
- Braschi E, Goyon V, Zunino R, Mohanty A, Xu L, McBride HM. Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr Biol. 2010;20:1310–1315. - PubMed
-
- Campanella M, Casswell E, Chong S, Farah Z, Wieckowski MR, Abramov AY, Tinker A, Duchen MR. Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1. Cell Metab. 2008;8:13–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous